Tag: Cinacalcet

Clinical trials indicate that up to 21% of patients treated with cinacalcet may experience diarrhea. This common side effect is a well-documented gastrointestinal issue associated with the medication, which is used to manage conditions like hyperparathyroidism and parathyroid carcinoma.

The U.S. Food and Drug Administration (FDA) first approved generic versions of cinacalcet on March 8, 2018. This milestone introduced competition for the brand-name drug Sensipar, which had sales of $1.72 billion in 2017. The question of *when did cinacalcet go generic?* is pivotal for understanding patient access and cost.

For many patients, cinacalcet is an effective treatment for hyperparathyroidism, but clinical studies and anecdotal reports show a significant incidence of gastrointestinal side effects, prompting the need for alternatives. Understanding the available treatment options is crucial for achieving optimal management of the condition, especially in those with chronic kidney disease (CKD).

In 2004, cinacalcet was approved by the FDA as the first agent in its class, definitively answering the question, 'What category is cinacalcet?' and ushering in a new treatment option for hyperparathyroidism. This medication is classified as a calcimimetic agent and is used to manage specific conditions involving overactive parathyroid glands.

Between 25% and 66% of patients taking cinacalcet report significant gastrointestinal side effects, such as nausea and vomiting, leading many to seek alternative treatments. Deciding what can be used instead of cinacalcet is a complex process that depends on the specific type of hyperparathyroidism, patient tolerance, and other co-existing medical conditions.

For many patients with chronic conditions such as secondary hyperparathyroidism or certain forms of parathyroid cancer, cinacalcet therapy is a long-term or even lifelong commitment. The precise length of time for how long can you take cinacalcet for is highly dependent on the underlying condition, the patient's individual response to treatment, and consistent medical supervision.

Cinacalcet is a prescription-only medication, approved by the FDA for treating serious conditions related to parathyroid hormone imbalances. This strict classification is why you cannot **buy cinacalcet over the counter**, as its use requires careful medical oversight to manage efficacy and potential side effects.

Cinacalcet (brand name Sensipar) is a calcimimetic agent that works by increasing the sensitivity of the calcium-sensing receptors on the parathyroid glands to extracellular calcium. It is an important medication for controlling high parathyroid hormone (PTH) levels, and the generic version offers a potentially more affordable option for many patients.

A 2024 meta-analysis revealed that the global prevalence of secondary hyperparathyroidism (SHPT) due to chronic kidney disease (CKD) is approximately 49.5% [1.7.1, 1.7.2]. A key medication to manage this is cinacalcet, but what's another name for cinacalcet? The most common brand name is Sensipar [1.2.1].

In a study involving chronic dialysis patients with uncontrolled secondary hyperparathyroidism, combination therapy with low-dose cinacalcet and calcitriol proved more effective than calcitriol alone. This approach leverages complementary mechanisms of action to better manage parathyroid hormone levels, highlighting that you can take cinacalcet and Calcitriol together under a doctor's supervision.